12 results on '"Dorenbaum, Alejandro"'
Search Results
2. Two-Dose Intrapartum/Newborn Nevirapine and Standard Antiretroviral Therapy to Reduce Perinatal HIV Transmission: A Randomized Trial.
- Author
-
Dorenbaum, Alejandro, Cunningham, Coleen K., Gelber, Richard D., Culnane, Mary, Mofenson, Lynne, Britto, Paula, Rekacewicz, Claire, Newell, Marie-Louise, Delfraissy, Jean Francois, Cunningham-Schrader, Bethann, Mirochnick, Mark, and Sullivan, John L.
- Subjects
- *
HIV infection transmission , *PERINATOLOGY , *NEONATAL diseases , *HIV-positive women , *MEDICAL care - Abstract
Context: A 2-dose intrapartum/newborn nevirapine regimen reduced perinatal human immunodeficiency virus (HIV) transmission in Ugandan women not receiving antenatal antiretroviral therapy (ART). However, it is unknown whether the addition of the 2-dose nevirapine regimen to standard ART would further reduce perinatal HIV transmission. Objective: To determine whether a 2-dose nevirapine regimen can decrease perinatal transmission of HIV in nonbreastfeeding women receiving standard ART. Design and Setting: International, blinded, placebo-controlled, phase 3 trial enrolling women between May 1997 and June 2000 at clinical sites providing care for HIV infection throughout the United States, Europe, Brazil, and the Bahamas. Participants: A total of 1270 women received nevirapine (n = 642) or placebo (n = 628). Infants were followed up for 6 months to determine HIV-infection status, which was available for 1248 deliveries. Intervention: A 200-mg dose of oral nevirapine to women after onset of labor and a 2-mg/kg dose of oral nevirapine to newborns between 48 and 72 hours after birth. Main Outcome Measures: Detection of HIV infection in infants and grade 3 and 4 toxic effects in women and newborns. Results: After review by the data and safety monitoring board, the trial was stopped early because the overall transmission rates were significantly lower than assumed for the study design. Antenatal ART included zidovudine alone in 23%; combinations without protease inhibitors in 36%; and combinations with protease inhibitors in 41%. Thirty-four percent of women had elective cesarean delivery. No significant safety concerns were identified for women or infants. Detection of HIV infection occurred in 9 (1.4%; 95% confidence interval [CI], 0.6%-2.7%) of 631 nevirapine group deliveries and 10 (1.6%; 95% CI, 0.8%-2.9%) of 617 placebo group deliveries. The 95% CI for the difference in transmission rate (-0.2) between the 2 study arms ranged from -1.5% in favor of nevirapine to 1... [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
3. Treatment of VLCAD-Deficient Patient Fibroblasts with Peroxisome Proliferator-Activated Receptor δ Agonist Improves Cellular Bioenergetics.
- Author
-
D'Annibale, Olivia M., Phua, Yu Leng, Van't Land, Clinton, Karunanidhi, Anuradha, Dorenbaum, Alejandro, Mohsen, Al-Walid, and Vockley, Jerry
- Subjects
- *
PEROXISOME proliferator-activated receptors , *BIOENERGETICS , *ADOLESCENCE , *FIBROBLASTS , *GENE expression , *MISSENSE mutation - Abstract
Background: Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency is an autosomal recessive disease that prevents the body from utilizing long-chain fatty acids for energy, most needed during stress and fasting. Symptoms can appear from infancy through childhood and adolescence or early adulthood, and include hypoglycemia, recurrent rhabdomyolysis, myopathy, hepatopathy, and cardiomyopathy. REN001 is a peroxisome-proliferator-activated receptor delta (PPARδ) agonist that modulates the expression of the genes coding for fatty acid β-oxidation enzymes and proteins involved in oxidative phosphorylation. Here, we assessed the effect of REN001 on VLCAD-deficient patient fibroblasts. Methods: VLCAD-deficient patient and control fibroblasts were treated with REN001. Cells were harvested for gene expression analysis, protein content, VLCAD enzyme activity, cellular bioenergetics, and ATP production. Results: VLCAD-deficient cell lines responded differently to REN001 based on genotype. All cells had statistically significant increases in ACADVL gene expression. Small increases in VLCAD protein and enzyme activity were observed and were cell-line- and dose-dependent. Even with these small increases, cellular bioenergetics improved in all cell lines in the presence of REN001, as demonstrated by the oxygen consumption rate and ATP production. VLCAD-deficient cell lines containing missense mutations responded better to REN001 treatment than one containing a duplication mutation in ACADVL. Discussion: Treating VLCAD-deficient fibroblasts with the REN001 PPARδ agonist results in an increase in VLCAD protein and enzyme activity, and a decrease in cellular stress. These results establish REN001 as a potential therapy for VLCADD as enhanced expression may provide a therapeutic increase in total VLCAD activity, but suggest the need for mutation-specific treatment augmented by other treatment measures. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study.
- Author
-
Gonzales, Emmanuel, Hardikar, Winita, Stormon, Michael, Baker, Alastair, Hierro, Loreto, Gliwicz, Dorota, Lacaille, Florence, Lachaux, Alain, Sturm, Ekkehard, Setchell, Kenneth D R, Kennedy, Ciara, Dorenbaum, Alejandro, Steinmetz, Jana, Desai, Nirav K, Wardle, Andrew J, Garner, Will, Vig, Pamela, Jaecklin, Thomas, Sokal, Etienne M, and Jacquemin, Emmanuel
- Subjects
- *
GENETIC disorders , *BILE acids , *SYNDROMES , *ITCHING , *SYNDROMES in children , *LEAST squares , *RESEARCH , *CLINICAL trials , *RESEARCH methodology , *MEDICAL cooperation , *EVALUATION research , *MEMBRANE glycoproteins , *ALAGILLE syndrome , *TREATMENT effectiveness , *COMPARATIVE studies , *RANDOMIZED controlled trials , *CARRIER proteins , *CHEMICAL inhibitors - Abstract
Background: Alagille syndrome is a rare genetic disease that often presents with severe cholestasis and pruritus. There are no approved drugs for management. Maralixibat, an apical, sodium-dependent, bile acid transport inhibitor, prevents enterohepatic bile acid recirculation. We evaluated the safety and efficacy of maralixibat for children with cholestasis in Alagille syndrome.Methods: ICONIC was a placebo-controlled, randomised withdrawal period (RWD), phase 2b study with open-label extension in children (aged 1-18 years) with Alagille syndrome (NCT02160782). Eligible participants had more than three times the normal serum bile acid (sBA) levels and intractable pruritus. After 18 weeks of maralixibat 380 μg/kg once per day, participants were randomly assigned (1:1) to continue maralixibat or receive placebo for 4 weeks. Subsequently, all participants received open-label maralixibat until week 48. During the long-term extension (204 weeks reported), doses were increased up to 380 μg/kg twice per day. The primary endpoint was the mean sBA change during the RWD in participants with at least 50% sBA reduction by week 18. Cholestastic pruritus was assessed using observer-rated, patient-rated, and clinician-rated 0-4 scales. The safety population was defined as all participants who had received at least one dose of maralixibat. This trial was registered with ClinicalTrials.gov, NCT02160782, and is closed to recruitment.Findings: Between Oct 28, 2014, and Aug 14, 2015, 31 participants (mean age 5·4 years [SD 4·25]) were enrolled and 28 analysed at week 48. Of the 29 participants who entered the randomised drug withdrawal period, ten (34%) were female and 19 (66%) were male. In the RWD, participants switched to placebo had significant increases in sBA (94 μmol/L, 95% CI 23 to 164) and pruritus (1·7 points, 95% CI 1·2 to 2·2), whereas participants who continued maralixibat maintained treatment effect. This study met the primary endpoint (least square mean difference -117 μmol/L, 95% CI -232 to -2). From baseline to week 48, sBA (-96 μmol/L, -162 to -31) and pruritus (-1·6 pts, -2·1 to -1·1) improved. In participants who continued to week 204 (n=15) all improvements were maintained. Maralixibat was generally safe and well tolerated throughout. The most frequent adverse events were gastrointestinal related. Most adverse events were self-limiting in nature and mild-to-moderate in severity.Interpretation: In children with Alagille syndrome, maralixibat is, to our knowledge, the first agent to show durable and clinically meaningful improvements in cholestasis. Maralixibat might represent a new treatment paradigm for chronic cholestasis in Alagille syndrome.Funding: Mirum Pharmaceuticals. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
5. Nevirapine.
- Author
-
Mirochnick, Mark, Clarke, Diana F., and Dorenbaum, Alejandro
- Subjects
- *
ANTIVIRAL agents , *PHARMACOKINETICS - Abstract
Nevirapine is a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase. It is effective when used as part of combination therapy to treat HIV-1-infected individuals and as monotherapy for prevention of mother-to-child HIV-1 transmission. Nevirapine pharmacokinetics are characterised by rapid absorption and distribution, followed by prolonged elimination. Nevirapine is generally well tolerated. The most common toxicity is rash, which is usually mild and selflimiting. The primary route of nevirapine elimination is through metabolism by the cytochrome P450 enzyme system. Nevirapine elimination accelerates during long term administration because of autoinduction of the enzymes involved in its elimination pathway. The recommended regimen for adults is nevirapine 200mg once daily for 2 weeks, followed by 200mg twice daily. Nevirapine elimination is prolonged in pregnant women during labour and in newborns. A regimen of a single 200mg oral dose administered to the mother during labour and a single 2 mg/kg dose administered to the newborn at 48 to 72 hours after birth maintains serum nevirapine concentrations above 100 µg/L (10 times the in vitro 50% inhibitory concentration against wild-type HIV-1) throughout the first week of life. This limited regimen has been shown to be extremely well tolerated and to reduce mother-to-child transmission by nearly 50% in mothers and infants receiving no other antiretrovirals. There are few data describing the safety and pharmacokinetics of nevirapine during long term use in pregnancy. In children, nevirapine elimination accelerates during the first years of life, reaching a maximum at around 2 years of age, followed by a gradual decline during the rest of childhood. Children should receive 4 mg/kg once daily for the first 2 weeks of therapy, followed by 7 mg/kg doses twice daily if below the age of 8 years or 4 mg/kg twice daily if older than 8 years. Alternatively, children may receive 150 mg/m² across all ages,... [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
6. Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial.
- Author
-
Tiessen, Renger G., Kennedy, Ciara A., Keller, Bradley T., Levin, Nancy, Acevedo, Lisette, Gedulin, Bronislava, van Vliet, Andre A., Dorenbaum, Alejandro, and Palmer, Melissa
- Subjects
- *
FATTY liver , *RANDOMIZED controlled trials , *CLINICAL drug trials , *DRUG efficacy , *PLACEBOS - Abstract
Background: Pathogenesis in non-alcoholic steatohepatitis (NASH) involves abnormal cholesterol metabolism and hepatic accumulation of toxic free cholesterol. Apical sodium-dependent bile acid transporter (ASBT) inhibition in the terminal ileum may facilitate removal of free cholesterol from the liver by reducing recirculation of bile acids (BAs) to the liver, thereby stimulating new BA synthesis from cholesterol. The aim of this phase 1 study in adult healthy volunteers (HVs) and patients with type 2 diabetes mellitus (T2DM) was to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ASBT inhibition with volixibat (SHP626; formerly LUM002).Methods: Participants were randomised 3:1 to receive once-daily oral volixibat (0.5 mg, 1 mg, 5 mg or 10 mg) or placebo for 28 days in two cohorts (HV and T2DM). Assessments included safety, faecal BA and serum 7α-hydroxy-4-cholesten-3-one (C4; BA synthesis biomarker).Results: Sixty-one individuals were randomised (HVs: placebo, n = 12; volixibat, n = 38; T2DM: placebo, n = 3; volixibat, n = 8). No deaths or treatment-related serious adverse events were reported. Mild or moderate gastrointestinal adverse events were those most frequently reported with volixibat. With volixibat, mean total faecal BA excretion on day 28 was ~1.6-3.2 times higher in HVs (643.73-1239.3 μmol/24 h) and ~8 times higher in T2DM (1786.0 μmol/24 h) than with placebo (HVs: 386.93 μmol/24 h; T2DM: 220.00 μmol/24 h). With volixibat, mean C4 concentrations increased by ~1.3-5.3-fold from baseline to day 28 in HVs and by twofold in T2DM.Conclusions: Volixibat was generally well tolerated. Increased faecal BA excretion and serum C4 levels support the mechanistic rationale for exploring ASBT inhibition in NASH. The study was registered with the Dutch clinical trial authority (Centrale Commissie Mensgebonden Onderzoek; trial registration number NL44732.056.13; registered 24 May 2013). [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
7. Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial.
- Author
-
Longo, Nicola, Harding, Cary O., Burton, Barbara K., Grange, Dorothy K., Vockley, Jerry, Wasserstein, Melissa, Rice, Gregory M., Dorenbaum, Alejandro, Neuenburg, Jutta K., Musson, Donald G., Zhonghua Gu, and Sile, Saba
- Subjects
- *
PHENYLKETONURIA , *PHENYLALANINE hydroxylase , *TYROSINE , *PHENYLALANINE , *ANABAENA variabilis , *PHENYLALANINE ammonia lyase , *PLANT enzymes , *POLYETHYLENE glycol - Abstract
Phenylketonuria is an inherited disease caused by impaired activity of phenylalanine hydroxylase, the enzyme that converts phenylalanine to tyrosine, leading to accumulation of phenylalanine and subsequent neurocognitive dysfunction. Phenylalanine ammonia lyase is a prokaryotic enzyme that converts phenylalanine to ammonia and trans-cinnamic acid. We aimed to assess the safety, tolerability, pharmacokinetic characteristics, and efficacy of recombinant Anabaena variabilis phenylalanine ammonia lyase (produced in Escherichia coli) conjugated with polyethylene glycol (rAvPAL-PEG) in reducing phenylalanine concentrations in adult patients with phenylketonuria. Methods In this open-label, phase 1, multicentre trial, single subcutaneous injections of rAvPAL-PEG were given in escalating doses (0⋅001, 0⋅003, 0⋅010, 0⋅030, and 0⋅100 mg/kg) to adults with phenylketonuria. Participants aged 18 years or older with blood phenylalanine concentrations of 600 µmol/L or higher were recruited from among patients attending metabolic disease clinics in the USA. The primary endpoints were safety and tolerability of rAvPAL-PEG. Secondary endpoints were the pharmacokinetic characteristics of the drug and its effect on concentrations of phenylalanine. Participants and investigators were not masked to assigned dose group. This study is registered with ClinicalTrials.gov, number NCT00925054. Findings 25 participants were recruited from seven centres between May 6, 2008, and April 15, 2009, with five participants assigned to each escalating dose group. All participants were included in the safety population. The most frequently reported adverse events were injection-site reactions and dizziness, which were self-limited and without sequelae. Two participants had serious adverse reactions to intramuscular medroxyprogesterone acetate, a drug that contains polyethylene glycol as an excipient. Three of five participants given the highest dose of rAvPAL-PEG (0⋅100 mg/kg) developed a generalised skin rash. By the end of the study, all participants had developed antibodies against polyethylene glycol, and some against phenylalanine ammonia lyase as well. Drug concentrations peaked about 89--106 h after administration of the highest dose. Treatment seemed to be effective at reducing blood phenylalanine in all five participants who received the highest dose (mean reduction of 54⋅2% from baseline), with a nadir about 6 days after injection and an inverse correlation between drug and phenylalanine concentrations in plasma. Phenylalanine returned to near-baseline concentrations about 21 days after the injection. Interpretation Subcutaneous administration of rAvPAL-PEG in a single dose of up to 0⋅100 mg/kg was fairly safe and well tolerated in adult patients with phenylketonuria. At the highest dose tested, rAvPAL-PEG reduced blood phenylalanine concentrations. In view of the development of antibodies against polyethylene glycol (and in some cases against phenylalanine ammonia lyase), future studies are needed to assess the effect of repeat dosing. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
8. When the Time Comes To Talk About HIV: Factors Associated With Diagnostic Disclosure and Emotional Distress in HIV-Infected Children.
- Author
-
Lester, Patricia, Chesney, Margaret, Cooke, Molly, Weiss, Robert, Whalley, Patrick, Perez, Berenice, Glidden, David, Petru, Ann, Dorenbaum, Alejandro, and Wara, Diane
- Subjects
- *
HIV-positive persons , *JUVENILE diseases , *DISCLOSURE - Abstract
Determines factors related to the timing and probability of nondisclosure of HIV status to perinatally HIV-infected children. Intelligence quotient; Family expressiveness; Occurrence of major life events.
- Published
- 2002
- Full Text
- View/download PDF
9. Development of Resistance Mutations in Women Receiving Standard Antiretroviral Therapy Who Received Intrapartum Nevirapine to Prevent Perinatal Human Immunodeficiency Virus Type 1 Transmission: A Substudy of Pediatric AIDS Clinical Trials Group Protocol 3
- Author
-
Cunningham, Coleen K., Chaix, Marie-Laure, Rekacewicz, Claire, Britto, Paula, Rouzioux, Christine, Gelber, Richard D., Dorenbaum, Alejandro, Delfraissy, Jean Francois, Bazin, Brigitte, Mofenson, Lynne, and Sullivan, John L.
- Subjects
- *
AIDS in children , *CLINICAL trials , *ANTIRHEUMATIC agents - Abstract
Pediatric AIDS Clinical Trials Group protocol 316 was an international, multicenter, placebo-controlled trial comparing single-dose oral nevirapine (200 mg to mother and 2 mg/kg to infant) with placebo in human immunodeficiency virus (HIV)-infected pregnant women receiving standard antiretroviral therapy. This substudy evaluated the emergence ofnevirapineresistance mutations at 6 weeks postpartum in a subgroup of participants. Maternal risk factors for the emergence of nevirapine-resistance mutations were evaluated. Mutations associated with nevirapine resistance were detectable at delivery, prior to receipt of study drug, in 5 (2.3%) of 217 women. Fourteen (15%; 95% confidence interval, 8%-23%) of 95 women who received intrapartum nevirapine developed a nevirapine-resistance mutation 6 weeks postpartum. The most common mutation was K103N, which was present in 10 women. The risk for development of a new nevirapine-resistance mutation did not correlate with CD4 cell count or HIV-1 RNA load at delivery or with type of antepartum antiretroviral therapy. The risk of nevirapine resistance should be considered when determining the risks or benefits of intrapartum nevirapine in women receiving antepartum antiretroviral therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2002
10. Diagnostic Disclosure to HIV-Infected Children: How Parents Decide When and What to Tell.
- Author
-
Lester, Patricia, Chesney, Margaret, Cooke, Molly, Whalley, Patrick, Perez, Berenice, Petru, Ann, Dorenbaum, Alejandro, and Wara, Diane
- Subjects
- *
VIRAL diseases in children , *HIV-positive persons , *PARENT-child relationships - Abstract
The objective of this study was to assess parental decision-making about illness disclosure to human immunodeficiency virus (HIV)-infected children. This is a cross-sectional study of 51 children with HIV infection based on parent interviews, child cognitive testing, clinical assessments and medical records. Only 43% of children had been told their HIV diagnosis. Qualitative analysis of parental decisionmaking about illness disclosure varied by child developmental level. Factors influencing parental decision to disclose the child's HIV status including parental communication style, parental illness, child's rights, treatment adherence, child questions and provider pressures, whereas concerns about HIV stigma and potential emotional distress were most frequently identified as reasons for nondisclosure. Central decision-making factors for parental HIV disclosure and reported outcomes of disclosure are described. Pediatric HIV disclosure represents a complex task for parents caring for the HIV-infected child, one in which the child's development and the family's community should be considered in the setting of a potentially stigmatizing infectious illness. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
11. PS-193-Phase 2 open-label study with a placebo-controlled drug withdrawal period of the apical sodium-dependent bile acid transporter inhibitor maralixibat in children with Alagille Syndrome: 48-week interim efficacy analysis.
- Author
-
Gonzales, Emmanuel, Sturm, Ekkehard, Stormon, Michael, Sokal, Etienne, Hardikar, Winita, Lacaille, Florence, Gliwicz, Dorota, Hierro, Loreto, Jaecklin, Thomas, Gu, Joan, Desai, Nirav K., Dorenbaum, Alejandro, Kennedy, Ciara, Baker, Alastair, and Jacquemin, Emmanuel
- Subjects
- *
CANAGLIFLOZIN , *BILE acids , *RESPIRATORY infections - Published
- 2019
- Full Text
- View/download PDF
12. When Parents Reject Interventions to Reduce Postnatal Human Immunodeficiency Virus Transmission.
- Author
-
Wolf, Lelsie E., Lo, Bernard, Beckerman, Karen P., Dorenbaum, Alejandro, Kilpatrick, Sarah J., and Weintrub, Peggy S.
- Subjects
- *
HIV infection transmission , *CHILDREN of AIDS patients - Abstract
Presents a summary of a study which legal and ethical issues when parents reject interventions to reduce postnatal human immunodeficiency virus transmission. Methodology; Results; Conclusion.
- Published
- 2002
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.